<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031339</url>
  </required_header>
  <id_info>
    <org_study_id>3366</org_study_id>
    <nct_id>NCT04031339</nct_id>
  </id_info>
  <brief_title>Study of Clinical Outcomes of Thyroid Cancer</brief_title>
  <acronym>ITCO</acronym>
  <official_title>Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italian Thyroid Cancer Observatory (ITCO) Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on
      thyroid cancer management in a prospective and consecutive series of newly-diagnosed
      patients, enrolled in centers uniformly distributed across the nation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little information is available on current practices in the treatment of thyroid cancer: a
      web-based thyroid cancer database was created to collect real-life data. The participants'
      network include tertiary referral centers operating at the national level, as well as smaller
      hospital-based units with local or regional recruitment areas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease persistence or recurrence</measure>
    <time_frame>Up to 10 years from the primary treatment</time_frame>
    <description>Composite event of disease persistence or recurrence during clinical follow-up, detected by any of the available imaging tools (neck sonography, computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease persistence after 12-18 months from the primary treatment</measure>
    <time_frame>12-18 months from the primary treatment</time_frame>
    <description>Rate of disease persistence after 12-18 months from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease recurrence after 3, 5 and 10 years from the primary treatment</measure>
    <time_frame>3, 5 and 10 years from the primary treatment</time_frame>
    <description>Rate of disease recurrence after 3, 5 and 10 years from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to primary therapy</measure>
    <time_frame>1, 3, 5 and 10 years after therapy</time_frame>
    <description>Response to primary treatment, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to secondary treatments</measure>
    <time_frame>1, 3, 5 and 10 years after therapy</time_frame>
    <description>Response to secondary treatments, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET])</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with thyroid cancer</arm_group_label>
    <description>Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance</description>
    <arm_group_label>Patients diagnosed with thyroid cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients prospectively and consecutively diagnosed with histologically-confirmed papillary,
        follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologically confirmed thyroid cancer

          -  clinical follow-up including serum thyroglobulin (Tg) assays, circulating Tg
             antibodies, and high-resolution gray-scale and color Doppler US of the thyroid bed and
             cervical lymph node compartments. Additional imaging studies and/or fine-needle
             aspiration biopsy for cytology are ordered at the examiner's discretion in accordance
             with evidence-based guidelines

          -  entire follow-up at a participating clinical center.

        Exclusion Criteria:

          -  patients referred to the recruiting centers ≥12 months from the primary treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Filetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Full professor of Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cosimo Durante, MD,PhD</last_name>
    <email>cosimo.durante@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giorgio Grani, MD,PhD</last_name>
    <email>giorgio.grani@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Taccaliti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Bologna, S. Orsola Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uberto Pagotto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Petrone, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnoldo Piccardo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome, Santa Maria Goretti Hospital</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Centanni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tinchi Pisticci Hospital</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco Bruno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Milan, Fondazione IRCCS, National Cancer Institute of Milan</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Piazza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Madeo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Salvatore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graziano Ceresini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bio-Medical Campus University</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Crescenzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome, Sant'Andrea Hospital</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Monti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <zip>I-00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosimo Durante, MD, PhD</last_name>
      <email>cosimo.durante@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Giorgio Grani, MD,PhD</last_name>
      <email>giorgio.grani@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Rosa Falcone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Ramundo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Castagna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Turin, Gradenigo Hospital</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Orlandi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Turin, Molinette Hospital</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Arvat, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.itcofoundation.org</url>
    <description>ITCO Foundation homepage</description>
  </link>
  <results_reference>
    <citation>Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, Durante C. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453. Epub 2017 Nov 30.</citation>
    <PMID>29192093</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone P, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Spiazzi G, Mian C, Persani L, Barbaro D, Nicolucci A, Filetti S. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. Thyroid. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299. Epub 2017 Nov 10.</citation>
    <PMID>29020892</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Sebastiano Filetti</investigator_full_name>
    <investigator_title>Full Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>papillary thyroid cancer</keyword>
  <keyword>follicular thyroid cancer</keyword>
  <keyword>poorly differentiated thyroid cancer</keyword>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>medullary thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

